REGENXBIO Inc (NASDAQ: RGNX) is a clinical-stage gene therapy company that licenses its NAV Technology Platform, a portfolio of adeno-associated virus (AAV) vectors, to biotechnology and pharmaceutical companies for use in developing gene therapies across multiple disease indications. Revenue comes from up-front fees, annual fees, milestone payments, royalties on licensed product sales, and service fees earned under license and collaboration agreements. As of FY2025, two customers, Novartis Gene Therapies and Nippon Shinyaku, accounted for approximately 99% of total revenues, reflecting extreme customer concentration. RGNX has not generated revenue from commercial product sales of its own therapies as of the 10-K filed March 5, 2026. Its most advanced collaboration is with AbbVie on ABBV-RGX-314 for retinal diseases, under which RGNX received a $370.0 million up-front payment in November 2021 and is eligible for up to $1.38 billion in development and sales-based milestones, plus equal profit sharing on U.S. sales and tiered royalties on ex-U.S. sales.

Revenue model

Royalty and licensing model. Revenue consists of up-front fees, annual fees, development and sales-based milestone payments, sublicense fees, and royalties on net sales of licensed products. All revenues for FY2025 and FY2024 were derived solely from license, royalty, and service revenues under collaboration and license agreements. No commercial product revenue as of filing date.

Products and services

NAV Technology Platform: a library of proprietary AAV vectors (including AAV7, AAV8, AAV9, AAVrh10, AAVrh46) used to deliver therapeutic transgenes. Key pipeline asset: ABBV-RGX-314 (co-developed with AbbVie), an investigational gene therapy for wet age-related macular degeneration and diabetic retinopathy delivered via subretinal or suprachoroidal administration. The company also designs novel AAV vectors with enhanced tissue specificity and optimized promoter/enhancer combinations for sustained gene expression.

Customers and end markets

Licensees and collaboration partners are biotechnology and pharmaceutical companies. Two customers, Novartis Gene Therapies and Nippon Shinyaku, represented approximately 99% of total revenues for FY2025. One customer, Novartis Gene Therapies, represented approximately 98% of total revenues for FY2024. End markets served through licensees include retinal diseases, and other genetic disease indications addressed via AAV gene therapy.

Value-chain role

Upstream IP licensor and platform technology provider in the gene therapy value chain. RGNX owns and licenses AAV vector intellectual property, conducts manufacturing for clinical development and U.S. commercial supply of ABBV-RGX-314 under the AbbVie collaboration, and performs development services. Commercialization of licensed products is led by licensees and collaboration partners.

Geographic exposure

Not disaggregated by geography in the provided excerpts. The AbbVie collaboration includes U.S. profit sharing and ex-U.S. royalties, indicating international rights are held by AbbVie outside the United States.

Competitors

4D Molecular Therapeutics, Amicus Therapeutics, Astellas Pharma, BioMarin Pharmaceutical, Eli Lilly, MeiraGTx, Novartis AG, Passage Bio, PTC Therapeutics, Roche, Sanofi, Sarepta Therapeutics, Solid Biosciences, Taysha Gene Therapies

Source: SEC 10-K, filed 2026-03-05

Industry: Biological Products, (No Diagnostic Substances) Peers: Avidity Biosciences, Inc. Cogent Biosciences Inc Crinetics Pharmaceuticals Inc Emergent BioSolutions Inc Erasca Inc Forma Therapeutics Holdings, Inc. ImmunoGen, Inc. Keros Therapeutics Inc Morphic Holding, Inc.